Objective: To compare the efficacy of albumin to normal saline (NS) for initial hydration therapy for dehydrated term infants with severe metabolic acidosis due to acute diarrhea.
Introduction
Although sodium bicarbonate is the most widely used buffer for the treatment of metabolic acidosis, hypovolemic infants with severe metabolic acidosis may require intravascular fluid administration as supplemental fluid management to correct their dehydration. Therefore, neonates with severe dehydration and metabolic acidosis require acute intervention to ensure adequate tissue perfusion as well as correction of metabolic acidosis. Normal saline (NS) is frequently used for volume expansion during the neonatal period; however, NS has no known buffering capacity. As a serum protein, albumin has histidine residues with a pKa of approximately 7.4; it shows a buffering effect in the acid-base balance and influences the pH. 1 Although there is a dispute concerning the efficacy of albumin infusion for neonatal metabolic acidosis, albumin infusion to improve pH and/or base deficits in acidotic infants may be clinically useful. [2] [3] [4] [5] [6] However, to date there are no randomized studies assessing the efficacy of albumin infusion for the treatment of neonatal metabolic acidosis; in addition, there are no studies on its efficacy when combined with sodium bicarbonate.
Therefore, the aim of our study was to compare the efficacy of albumin to NS for initial hydration therapy in dehydrated term infants with moderate and severe metabolic acidosis, especially with regard to buffering effects.
Methods
Infants admitted to Ansan Hospital, Korea University Medical Center, who developed moderate-to-severe dehydration with metabolic acidosis, due to acute watery diarrhea within the first month of life, were eligible for this study. Patients were enrolled between September 2002 and December 2003. The study protocol was approved by the local research ethics committee at Ansan Hospital, and written parental informed consent was obtained in all cases. The information collected on all of the participating neonates included age, initial birth weight, body weight, complete blood count, electrolytes, blood urea nitrogen, creatinine, protein, albumin and blood gas analysis, as well as physical findings such as a dry tongue or lips, depressed fontanel, sunken eyes, decreased urination and decreased activity.
Initially, 78 neonates who had symptoms or signs of dehydration were eligible for a diagnosis of moderate-to-severe dehydration. 7 Among them, 33 were included because their initial pH was below 7.25 or their initial base excess (BE) was below À15. Neonates without metabolic acidosis were excluded. All neonates were born full term and were healthy at the time of delivery.
After randomization, 5% albumin (10 ml kg À1 ) and NS (10 ml kg À1 ) were administrated to infants in the albumin group (n ¼ 15) and in the NS group (n ¼ 18) as open label initial hydration therapy. All patients were treated in accordance with our standard treatment protocol that included sodium bicarbonate supplements (0.3 Â weight (Kg) Â BE Â 1/2), maintenance fluid (5% dextrose/NaCl 20 mEq l À1 at a rate 4 ml kg À1 h À1 ) and potassium supplements (if the plasma potassium level was <3.0 mEq l À1 ). At 3 h after initial hydration, arterial blood gas analysis was performed as a measure of the short-term effects of the 5% albumin or NS therapy. If there was a sustained metabolic acidosis (pH <7.25 or BE <À15), additional infusion with sodium bicarbonate was carried out. In addition, if patients did not urinate during the 3 h after initial hydration, an additional infusion with the same fluids as in initial hydration therapy (10 ml kg À1 , 5% albumin or NS) was performed.
Body weight and weight gain 4 days after treatment, as well as the length of hospital stay, were evaluated as long-term outcomes. At all times, usual feeding was allowed and oral rehydration solutions were administered during the rehydration and maintenance phases, except that severe vomiting made patients intolerant of oral feeding. Patients who were tolerant toward oral rehydration solutions were offered 100 ml kg À1 of the oral rehydration solution over 6 h. Ongoing losses due to vomiting and diarrhea were replaced with an additional 5 and 10 ml kg À1 of oral rehydration solution for each vomiting and diarrhea, respectively.
Pre-and post treatment values were compared using the paired t-test. Comparisons between the two treatment groups were performed by Student's t-test, Fisher's exact test and w 2 test.
Results
We found no significant statistical differences between the two groups in initial body weight at birth, body weight at admission, electrolytes, blood urea nitrogen, creatinine, total serum protein, albumin levels and the number of hypotensive neonates ( Table 1) . The results of the initial blood gas analysis showed moderate and severe metabolic acidosis and no significant difference between the albumin and NS groups. At 3 h after initial hydration, the pH, BE and HCO 3 À in both groups were significantly increased compared with the pretreatment values. However, there was no statistically significant difference in the magnitude of the improvements in the pH, BE and HCO 3 À levels between the two groups ( Table 2 ). In addition, there was no statistically significant difference in the frequency of sodium bicarbonate therapy and bolus hydration therapy (albumin or NS) between the two groups (Table 3) . Furthermore, there was no significant difference in body weight and ratio (%) of weight gain by the fourth day of treatment as well as in the length of hospital stay in comparisons between the albumin group (3097 ± 343 g, 5.08±6.33% and 8.13±3.23 day) and the NS group (3050 ± 397 g, 5.67 ± 5.73% and 9.36 ± 4.16 day).
Discussion
Traditionally, albumin has been widely used in many different clinical situations in neonatology. Currently, albumin is not recommended as first-line therapy because of many associated problems such as the potential risk of infection, hypersensitivity reactions, fluid overload, capillary leakage and high costs. However, the absence of albumin-related mortality has been documented in the medical literature. [8] [9] [10] In addition, there is a lack of evidence that albumin is associated with significant side effects such as infection. 11 The fact that some data in the literature have not shown increased mortality with albumin administration does not support its use, particularly in neonates with dehydration.
Studies have shown that NS was as effective as 5% albumin for the treatment of hypotensive preterm neonates during the first postnatal days; the albumin-treated infants, however, had a decreased ability to appropriately lose weight after treatment. 12, 13 Recently, however, Lynch et al.
14 reported that preterm infants with hypotension are more likely to respond favorably and to decrease subsequent use of dopamine after albumin bolus infusion compared with NS.
In the case of respiratory disease, albumin has not been shown to alter the duration of assisted ventilation and oxygen dependency. 15 By contrast, the infusion of colloidal fluid during the perinatal period in premature infants of median gestational age 27 weeks has been related to an increased duration of oxygen dependency and abnormal neurodevelopmental outcomes. 16, 17 In addition, albumin potentially causes deterioration of the protein leak syndrome of prematurity and lung function by deactivation of the surfactant in alveolar spaces. [18] [19] [20] There are a few studies on the effects of albumin administration in neonates with metabolic acidosis. Some studies have shown an increment of pH after albumin infusion. In one study, the administration of 4.5% albumin to ventilated, normotensive, very low birth weight infants with metabolic acidosis (pH <7.25) resulted in an immediate significant increase in pH and a BE 6 h post-infusion. 2 However, this study had no control group and the results therefore have limited value. Another study reported that albumin significantly increased pH compared with pretreatment values; however, bicarbonate was significantly more effective than albumin. 4 Although there was no improvement of pH, Dimitriou et al. 3 reported that the infusion of albumin improved the base deficit in hypotensive, very premature infants.
Prior to beginning our study, we predicted that albumin would be more effective than NS for correction of dehydration and acidosis in neonates. However, our results showed that albumin was not more effective than NS. There was no significant difference between the two groups after a comparison of the variables associated with the short-term effects (pH, BE and HCO 3 À ) and the long-term effects (body weight and weight gain 4 days after treatment and the length of hospital stay). We could not study the pure effects of albumin and NS on acidosis because sodium bicarbonate was required in all infants to treat severe metabolic acidosis; however, albumin was not more effective than NS given that all infants received sodium bicarbonate.
Maitland et al. 21 reported a randomized trial of volume expansion with albumin and NS in children with severe malaria. Their patients had a moderate-to-severe acidosis and dehydration; there was no significant difference in the resolution of acidosis in comparisons between the two groups. Their results were consistent with our study findings.
Recent studies have shown that polyelectrolyte solutions may offer a more effective approach. A comparison between NS and polyelectrolyte solutions for fluid resuscitation, in severely dehydrated infants with acute diarrhea, has shown that the polyelectrolyte solution was as effective as NS for volume expansion and better than saline for correcting acidosis by providing increased bicarbonate. 22 The results of our study showed that albumin was not more effective than NS for initial hydration treatment of dehydrated term infants accompanied by metabolic acidosis with respect to short-term and long-term prognostic variables. Therefore, infusion with albumin for the treatment of dehydrated neonates with metabolic acidosis does not appear to be indicated. Further studies are needed to evaluate the safety and efficacy of crystalloid fluid for treatment of severe dehydration with metabolic acidosis. Albumin group 7.15 ± 0.11 7.30 ± 0.08 0.16 ± 0.14 <0.001 À22.0 ± 4.6 À17.8 ± 3.2 4.2 ± 3.1 <0.001 6.9 ± 4.0 8.5 ± 3.0 1.6 ± 2.8 <0.05 Normal saline group 7.14 ± 0.12 7.31 ± 0.08 0.16 ± 0.13 <0.001 À22.0 ± 5.5 À15.9 ± 4.2 6.1 ± 3.6 <0.001 7.0 ± 4. 
